Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).
2018
3561Background: Single agent PD-1/L1 inhibition is efficacious in mismatch repair deficient tumours - about 5% of MCRC patients (pts). For the remaining MCRC pts the role of immunotherapy still nee...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
16
Citations
NaN
KQI